X

Trial Profile

A phase 1b/2 trial evaluating Etigilimab in combination with an anti-PD-1 antibody in Clear Cell Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etigilimab (Primary)
Indications Ovarian cancer
Focus Therapeutic Use
Sponsors Mereo BioPharma

Most Recent Events

27 Mar 2024 According to a Mereo BioPharma media release, an update may be provided by the investigator in the second half of 2024 or early 2025.
27 Mar 2024 According to a Mereo BioPharma media release, based on the results to-date, the study has been expanded from the initial 10 patients to 20 patients.
21 Sep 2023 Status changed from planning to recruiting, according to a Mereo Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com